Targeting these IRs has been validated as a promising therapeutic strategy against cancer, and potentially chronic infection, as illustrated by clinical success achieved with immune checkpoint blockade (ICB) using monoclonal antibodies (mAbs) against PD-1 and CTLA-4 in metastatic melanoma (2, 3). Here, CTLA4 is linked to cancer.